The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Accumulated OCI
Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.
The Oncology Institute, Inc.NASDAQ: TOI
Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026
Accumulated OCI remains negative
Q1 FY2026 Accumulated OCI was $0, compared with $0 a year earlier.
Context
- Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Accumulated OCI increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Accumulated OCI history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Accumulated OCI | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Accumulated OCI vs competitors
How TOI compares with its peers on the latest reported figures
- Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
- Accumulated OCI amounts to 0.0% of total assets for TOI, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AUNAAuna S.A. | Mar 2026 | PEN 696.45M PEN | +31.5% | — | 9.1% |
| Mar 2026 | $479K USD | -11.8% | — | 0.0% | |
CBLLCeriBell, Inc. | Mar 2026 | $18K USD | +400.0% | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | -$26K USD | -145.6% | — | 0.0% | |
| Mar 2026 | -$278K USD | +66.9% | — | 0.1% | |
| Mar 2026 | -$1.4M USD | +87.9% | — | 0.3% | |
| Mar 2026 | -$1.69M USD | -17.6% | — | 0.4% | |
| Mar 2026 | -$6.63M USD | +63.4% | — | 1.3% | |
| Peer median (excluding TOI) | — | +47.4% | — | 0.1% | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 114.3M | 14.01M | 33.49M | 49.67M | 33.57M |
| Short-term Investments | 0 | 59.8M | 49.37M | 0 | 0 |
| Net Receivables | 21.24M | 40.43M | 42.91M | 48.68M | 59.32M |
| Inventory | 6.44M | 9.26M | 13.68M | 10.04M | 16.88M |
| Other Current Assets | 875K | 0 | 0 | 4.03M | 2.99M |
| Total Current Assets | 154.06M | 130.42M | 143.49M | 112.42M | 112.75M |
| Property, Plant & Equipment (Net) | 4.19M | 33.04M | 40.05M | 37.67M | 33.06M |
| Goodwill | 26.63M | 21.42M | 7.23M | 7.23M | 7.23M |
| Intangible Assets | 18.25M | 17.96M | 17.9M | 14.81M | 11.02M |
| Long-term Investments | (371K) | 58.35M | 0 | 0 | 0 |
| Tax Assets | 371K | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 320K | 477K | 561K | 589K | 606K |
| Total Non-current Assets | 49.38M | 131.25M | 65.75M | 60.3M | 51.91M |
| Total Assets | 203.44M | 261.67M | 209.24M | 172.72M | 164.66M |
| Account Payables | 15.56M | 9.37M | 14.43M | 24.32M | 43.17M |
| Short-term Debt | 183K | 0 | 0 | 0 | 0 |
| Tax Payables | 132K | 255K | 0 | 0 | 0 |
| Deferred Revenue | 592K | 1.14M | 545K | 4.7M | 2.28M |
| Other Current Liabilities | 10.14M | 9.35M | 11.33M | 10.35M | 13.15M |
| Total Current Liabilities | 29.8M | 29.72M | 34.79M | 52.22M | 70.96M |
| Long-term Debt | 0 | 80.62M | 86.83M | 93.13M | 77.4M |
| Deferred Tax Liabilities | 371K | 108K | 32K | 32K | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 69.11M | 5.98M | 4.08M | 527K | 12.88M |
| Total Non-current Liabilities | 69.48M | 108.77M | 117.43M | 116.91M | 109.41M |
| Total Liabilities | 99.28M | 138.49M | 152.22M | 169.13M | 180.38M |
| Common Stock | 7K | 7K | 8K | 8K | 10K |
| Retained Earnings | (63.23M) | (63.08M) | (146.15M) | (210.81M) | (271.42M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 104.16M | 123.18M | 57.03M | 3.59M | (15.72M) |
| Total Debt | 183K | 108.18M | 119.68M | 123.15M | 103.69M |
| Net Debt | (114.12M) | 94.17M | 86.19M | 73.48M | 70.12M |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.